Smoak B L, DeFraites R F, Magill A J, Kain K C, Wellde B T
Division of Preventive Medicine, Walter Reed Army Institute of Research, Washington, District of Columbia, USA.
Am J Trop Med Hyg. 1997 Feb;56(2):231-4. doi: 10.4269/ajtmh.1997.56.231.
Different strains of Plasmodium vivax vary in their sensitivity to primaquine, the only drug that prevents relapses. Described are the clinical data and relapse pattern for 75 soldiers treated for vivax malaria since returning from Somalia. Following their initial attack of malaria, 60 of the 75 cases received a standard course of primaquine (15 mg base daily for 14 days). Twenty-six of the 60 soldiers subsequently relapsed for a failure rate of 43%. Eight soldiers had a second relapse following primaquine therapy after both the primary attack and first relapse. Three of these soldiers had received a higher dosage of primaquine (30 mg base daily for 14 days) after their second attack. The apparent ineffectiveness of primaquine therapy in preventing relapses suggests the presence of primaquine-resistant P. vivax strains in Somalia.
不同株间日疟原虫对伯氨喹（唯一一种预防复发的药物）的敏感性存在差异。本文描述了75名自索马里回国后接受间日疟治疗的士兵的临床数据和复发模式。在初次感染疟疾后，75例中的60例接受了标准疗程的伯氨喹治疗（每日15毫克碱基，共14天）。60名士兵中有26人随后复发，失败率为43%。8名士兵在初次发作和首次复发后接受伯氨喹治疗后出现第二次复发。其中3名士兵在第二次发作后接受了更高剂量的伯氨喹治疗（每日30毫克碱基，共14天）。伯氨喹治疗预防复发的明显无效表明索马里存在对伯氨喹耐药的间日疟原虫株。
